Celerion Becomes Cardiac Safety Research Consortium Member

Celerion announced its membership into the Cardiac Safety Research Consortium (CSRC) to engage with other thought leaders on key issues that impact cardiovascular safety. This will include discussions regarding alternative approaches to ICH E14 to assess arrhythmia liability in early drug development.

As a provider of cardiovascular safety services in early clinical research, Celerion's activity highlights the company's leadership role and contributions in cardiovascular safety evaluation, and allows it to collaborate in critical discussions to ensure we deliver on our clients’ and public health needs.

Read the full release here.